Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Safety and Efficacy Study of VEGFA-targeting Gene Therapy to Treat Refractory Retinal and Choroidal Neovascularization Diseases

NCT05099094 is registered in ClinicalTrials.gov with Shanghai BDgene Co., Ltd. as lead sponsor.

NCT NCT05099094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05099094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Safety and Efficacy Study of VEGFA-targeting Gene Therapy to Treat Refractory Retinal and Choroidal Neovascularization Diseases
Lead sponsor
Shanghai BDgene Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
November 25, 2021
Completion date
September 30, 2025
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, neovascular age-related macular degeneration, retinal vein occlusion